Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma of lung (disorder)
|
563 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.810 | 1.000 | 3 | 2012 | 2016 | |||||
Carcinoma of lung
|
1204 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.740 | 1.000 | 4 | 2016 | 2019 | |||||
Benign Prostatic Hyperplasia
|
91 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Lower Urinary Tract Symptoms
|
30 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Mean Corpuscular Volume (result)
|
549 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Prostate specific antigen measurement
|
95 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Malignant neoplasm of lung
|
1142 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.040 | 1.000 | 4 | 2016 | 2019 | |||||
Primary malignant neoplasm of lung
|
981 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.040 | 1.000 | 4 | 2016 | 2019 | |||||
Breast Carcinoma
|
2793 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.020 | 1.000 | 2 | 2012 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.020 | 1.000 | 2 | 2012 | 2018 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.020 | 1.000 | 2 | 2018 | 2019 | |||||
Adenocarcinoma
|
168 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Childhood Leukemia
|
140 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Chronic Obstructive Airway Disease
|
852 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Glioma
|
353 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Ischemic stroke
|
704 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
leukemia
|
144 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Malignant Neoplasms
|
1641 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Primary malignant neoplasm
|
1374 | 0.724 | 0.240 | 5 | 1287079 | 3 prime UTR variant | G/A | snv | 0.63 | 0.010 | 1.000 | 1 | 2012 | 2012 |